Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MedCap AB (publ) (MCAP.ST)
Solna, SE
MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature businesses, turnarounds, and outright buyouts. The company primarily directs its capital towards businesses within the healthcare sector, focusing on medical equipment and services, biotechnology, life sciences, and pharmaceuticals. It actively seeks unlisted, small to mid-sized companies located predominantly across Northern Europe. Equity investments typically fall within the SEK 25 million to SEK 150 million range (approximately $2.75 million to $16.51 million). Target companies generally exhibit an enterprise value and annual sales revenue between SEK 50 million and SEK 200 million ($5.90 million to $23.06 million), alongside an EBITDA of SEK 1 million to SEK 50 million ($0.11 million to $5.50 million). MedCap aims to acquire ownership stakes of 20% to 50% in its portfolio entities, financing these through its own capital, loans, and direct balance sheet investments. Established in 2001, the firm maintains its headquarters in Stockholm, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.77% | -9.97% | +6.29% | +4.19% | -7.10% | -4.32% | +17.11% | +63.99% | +132.88% | +1,445.45% | +3,823.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Asset Management: +17.4%+16.7% Q1'26: +12.7% (vs Q1'25)
-
EPS growth Asset Management: +22.7%+4.6% Q1'26: +10.4% (vs Q1'25)
-
FCF margin FCF growth · Asset Management: +27.7%+15.0% Q1'26: +8.5% (vs Q1'25)
-
EBIT margin Asset Management: +50.6%+15.2% Q1'26: +14.2% (vs Q1'25)
-
ROIC Asset Management: +6.5%+13.6% ★ Q1'26: +15.5% (vs Q1'25)
-
Share dilution Asset Management: +0.0%+1.2% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Asset Management: -0.03×1.49× Q1'26: 0.97× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
826.09M
est: 863.95M (-4.4%)
|
852.75M
est: 822.10M (+3.7%)
|
816.92M
est: 903.57M (-9.6%)
|
851.67M
est: 665.52M (+28.0%)
|
411.20M
est: 665.52M (-38.2%)
|
709.00M
est: 711.00M (-0.3%)
|
757.10M
est: 769.20M (-1.6%)
|
817.40M
est: 810.00M (+0.9%)
|
916.30M
est: 916.00M (+0.0%)
|
1.11B
est: 1.06B (+4.8%)
|
1.59B
est: 1.59B (+0.0%)
|
1.81B
est: 1.82B (-0.8%)
|
2.11B
est: 2.07B (+1.7%)
|
2.31B
2.31B – 2.31B
+11.5% YoY
|
2.44B
2.44B – 2.44B
+5.7% YoY
|
2.57B
2.54B – 2.59B
+5.2% YoY
|
3.47B
3.47B – 3.47B
+35.1% YoY
|
| EBITDA |
54.04M
est: 179.34M (-69.9%)
|
35.81M
est: 170.65M (-79.0%)
|
56.04M
est: 187.56M (-70.1%)
|
30.98M
est: 138.15M (-77.6%)
|
63.06M
est: 138.15M (-54.4%)
|
70.00M
est: 147.59M (-52.6%)
|
129.60M
est: 159.67M (-18.8%)
|
147.80M
est: 168.14M (-12.1%)
|
191.50M
est: 190.14M (+0.7%)
|
237.30M
est: 220.03M (+7.8%)
|
341.90M
est: 329.51M (+3.8%)
|
396.00M
est: 442.83M (-10.6%)
|
473.90M
est: 503.70M (-5.9%)
|
561.48M
561.48M – 561.48M
+11.5% YoY
|
593.40M
593.40M – 593.40M
+5.7% YoY
|
624.23M
618.56M – 629.90M
+5.2% YoY
|
843.14M
843.14M – 843.14M
+35.1% YoY
|
| EBIT |
33.94M
est: 121.90M (-72.2%)
|
15.93M
est: 115.99M (-86.3%)
|
32.88M
est: 127.49M (-74.2%)
|
3.55M
est: 93.90M (-96.2%)
|
13.00M
est: 93.90M (-86.2%)
|
44.10M
est: 100.32M (-56.0%)
|
81.50M
est: 108.53M (-24.9%)
|
90.60M
est: 114.29M (-20.7%)
|
126.40M
est: 129.24M (-2.2%)
|
168.40M
est: 149.56M (+12.6%)
|
237.90M
est: 223.97M (+6.2%)
|
280.60M
est: 305.67M (-8.2%)
|
320.50M
est: 347.68M (-7.8%)
|
387.56M
387.56M – 387.56M
+11.5% YoY
|
409.59M
409.59M – 409.59M
+5.7% YoY
|
430.87M
426.96M – 434.79M
+5.2% YoY
|
581.97M
581.97M – 581.97M
+35.1% YoY
|
| Net Income |
22.61M
est: 8.90M (+154.2%)
|
8.52M
est: 19.27M (-55.8%)
|
19.45M
est: 3.16M (+515.0%)
|
73.0K
est: 22.11M (-99.7%)
|
2.10M
est: 22.11M (-90.5%)
|
600.0K
est: 20.46M (-97.1%)
|
53.70M
est: 69.38M (-22.6%)
|
60.90M
est: 89.10M (-31.7%)
|
96.50M
est: 130.02M (-25.8%)
|
117.60M
est: 160.26M (-26.6%)
|
172.20M
est: 209.93M (-18.0%)
|
207.40M
est: 256.57M (-19.2%)
|
219.80M
est: 274.89M (-20.0%)
|
337.14M
337.14M – 337.14M
+22.6% YoY
|
378.55M
378.55M – 378.55M
+12.3% YoY
|
412.38M
412.38M – 412.38M
+8.9% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
88.31M
est: 182.20M (-51.5%)
|
87.45M
est: 173.37M (-49.6%)
|
95.26M
est: 190.56M (-50.0%)
|
125.97M
est: 140.35M (-10.2%)
|
64.50M
est: 140.35M (-54.0%)
|
114.20M
est: 149.94M (-23.8%)
|
89.10M
est: 162.22M (-45.1%)
|
109.40M
est: 170.82M (-36.0%)
|
111.90M
est: 193.18M (-42.1%)
|
-21.60M
est: 223.54M (-109.7%)
|
684.70M
est: 334.77M (+104.5%)
|
698.50M
est: 329.11M (+112.2%)
|
-36.80M
est: 374.35M (-109.8%)
|
417.29M
417.29M – 417.29M
+11.5% YoY
|
441.01M
441.01M – 441.01M
+5.7% YoY
|
463.92M
459.71M – 468.14M
+5.2% YoY
|
626.61M
626.61M – 626.61M
+35.1% YoY
|
| EPS |
1.90
est: 0.60 (+216.7%)
|
0.60
est: 1.30 (-53.8%)
|
1.50
est: 0.21 (+603.1%)
|
0.01
est: 1.49 (-99.6%)
|
0.20
est: 1.49 (-86.6%)
|
0.04
est: 1.38 (-96.8%)
|
3.99
est: 4.68 (-14.7%)
|
4.24
est: 6.01 (-29.5%)
|
6.52
est: 8.77 (-25.7%)
|
7.94
est: 10.81 (-26.5%)
|
11.63
est: 14.16 (-17.9%)
|
13.99
est: 17.10 (-18.2%)
|
14.67
est: 18.32 (-19.9%)
|
22.47
22.47 – 22.47
+22.6% YoY
|
25.23
25.23 – 25.23
+12.3% YoY
|
27.49
27.49 – 27.49
+8.9% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers MSCI Emerging Markets Swap UCITS ETF 1C XMMD.L | 0.27% | 3.36M | 0.49% |
| 2 | iShares MSCI Europe Small-Cap ETF IEUS | 0.04% | 70.2K | 0.41% |
| 3 | Avantis International Small Cap Equity ETF AVDS | 0.03% | 104.4K | 0.30% |
| 4 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.03% | 1.08M | 0.30% |
| 5 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 254.3K | 0.40% |
| 6 | Avantis International Small Cap Value ETF AVDV | 0.03% | 5.35M | 0.36% |
| 7 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.03% | 288.5K | 0.39% |
| 8 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.02% | 80.6K | 0.23% |
| 9 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.02% | 80.6K | 0.23% |
| 10 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.02% | 40.4K | 0.83% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anders Dahlberg | Chief Executive Officer | 6M | male |
| Anders Larnholt | Business Area Head Specialty Pharma | — | male |
| Kristina Ekblad | Chief Financial Officer | — | female |
| Lars Ångman | Investment Manager | — | male |
| Tove Christiansson | Business Area Head Assistive Tech | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MCAP.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
